IRLAB Therapeutics AB (publ) (IRLAB-A.ST)
SEK 11.25
(0.0%)
SEK 11.25
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -83.74 Million SEK | 66.34% |
| 2022 | -248.8 Million SEK | 37.06% |
| 2021 | -395.29 Million SEK | -44.23% |
| 2020 | -274.08 Million SEK | -158.61% |
| 2019 | -105.98 Million SEK | 21.17% |
| 2018 | -134.44 Million SEK | -79.95% |
| 2017 | -74.7 Million SEK | -194.87% |
| 2016 | -25.33 Million SEK | -80.66% |
| 2015 | -14.02 Million SEK | 28.69% |
| 2014 | -19.66 Million SEK | 0.0% |
| 2013 | - SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -45.53 Million SEK | 45.63% |
| 2024 Q2 | -45.63 Million SEK | -0.23% |
| 2024 Q3 | -34.47 Million SEK | 34.06% |
| 2023 Q3 | -117.51 Million SEK | 23.79% |
| 2023 Q2 | -154.21 Million SEK | 25.5% |
| 2023 Q4 | -83.74 Million SEK | 28.74% |
| 2023 Q1 | -207.01 Million SEK | 16.8% |
| 2023 FY | -83.74 Million SEK | 66.34% |
| 2022 Q1 | -362.19 Million SEK | 8.37% |
| 2022 Q3 | -287.41 Million SEK | 9.48% |
| 2022 FY | -248.8 Million SEK | 37.06% |
| 2022 Q4 | -248.8 Million SEK | 13.43% |
| 2022 Q2 | -317.51 Million SEK | 12.34% |
| 2021 Q3 | -423.83 Million SEK | -91.5% |
| 2021 FY | -395.29 Million SEK | -44.23% |
| 2021 Q1 | -245.12 Million SEK | 10.57% |
| 2021 Q4 | -395.29 Million SEK | 6.73% |
| 2021 Q2 | -221.32 Million SEK | 9.71% |
| 2020 Q2 | -198.17 Million SEK | 8.83% |
| 2020 FY | -274.08 Million SEK | -158.61% |
| 2020 Q4 | -274.08 Million SEK | -63.86% |
| 2020 Q3 | -167.27 Million SEK | 15.6% |
| 2020 Q1 | -217.36 Million SEK | -105.09% |
| 2019 FY | -105.98 Million SEK | 21.17% |
| 2019 Q2 | -91.59 Million SEK | 17.61% |
| 2019 Q4 | -105.98 Million SEK | -55.83% |
| 2019 Q3 | -68.01 Million SEK | 25.75% |
| 2019 Q1 | -111.16 Million SEK | 17.31% |
| 2018 Q2 | -170.17 Million SEK | -180.24% |
| 2018 FY | -134.44 Million SEK | -79.95% |
| 2018 Q3 | -151.91 Million SEK | 10.73% |
| 2018 Q1 | -60.72 Million SEK | 18.72% |
| 2018 Q4 | -134.44 Million SEK | 11.5% |
| 2017 FY | -74.7 Million SEK | -194.87% |
| 2017 Q1 | -120.03 Million SEK | -373.78% |
| 2017 Q2 | -106.81 Million SEK | 11.02% |
| 2017 Q3 | -96.09 Million SEK | 10.03% |
| 2017 Q4 | -74.7 Million SEK | 22.26% |
| 2016 Q1 | 14.42 Million SEK | 0.0% |
| 2016 FY | -25.33 Million SEK | -80.66% |
| 2016 Q4 | -25.33 Million SEK | 0.0% |
| 2015 FY | -14.02 Million SEK | 28.69% |
| 2014 FY | -19.66 Million SEK | 0.0% |
| 2013 FY | - SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -50.02 Million SEK | -67.416% |
| Ziccum AB (publ) | -2.13 Million SEK | -3818.718% |
| Modus Therapeutics Holding AB (publ) | -19.06 Million SEK | -339.365% |
| BioArctic AB (publ) | -606.58 Million SEK | 86.194% |
| Sprint Bioscience AB (publ) | -49.93 Million SEK | -67.707% |
| Mendus AB (publ) | -96.29 Million SEK | 13.034% |
| Genovis AB (publ.) | -43.94 Million SEK | -90.581% |
| Intervacc AB (publ) | -88.16 Million SEK | 5.01% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 20.51 Million SEK | 508.303% |
| Active Biotech AB (publ) | -33.2 Million SEK | -152.238% |
| Magle Chemoswed Holding AB (publ) | 53.22 Million SEK | 257.344% |
| Bio-Works Technologies AB (publ) | -39.38 Million SEK | -112.643% |
| Aptahem AB (publ) | 2.9 Million SEK | 2979.11% |
| Vicore Pharma Holding AB (publ) | -333.62 Million SEK | 74.899% |
| Kancera AB (publ) | -45.69 Million SEK | -83.277% |
| Infant Bacterial Therapeutics AB (publ) | -329.06 Million SEK | 74.551% |
| Fluicell AB (publ) | -2.76 Million SEK | -2930.872% |
| Saniona AB (publ) | 40.44 Million SEK | 307.044% |
| Lipigon Pharmaceuticals AB (publ) | -31.92 Million SEK | -162.295% |
| Biovica International AB (publ) | -58.73 Million SEK | -42.573% |
| Spago Nanomedical AB (publ) | -45.21 Million SEK | -85.202% |
| AcouSort AB (publ) | -23.98 Million SEK | -249.133% |
| Xintela AB (publ) | -7.8 Million SEK | -972.391% |
| Abliva AB (publ) | -57.24 Million SEK | -46.302% |
| Egetis Therapeutics AB (publ) | -194.7 Million SEK | 56.989% |
| Karolinska Development AB (publ) | -82.2 Million SEK | -1.875% |
| OncoZenge AB (publ) | -12.62 Million SEK | -563.206% |
| Amniotics AB (publ) | -5.63 Million SEK | -1386.914% |
| 2cureX AB (publ) | -13.4 Million SEK | -524.808% |
| CombiGene AB (publ) | -101.44 Million SEK | 17.446% |
| Asarina Pharma AB (publ) | -2.16 Million SEK | -3775.197% |
| Calliditas Therapeutics AB (publ) | 5.4 Million SEK | 1650.796% |
| Camurus AB (publ) | -1.16 Billion SEK | 92.814% |
| Corline Biomedical AB | -17.01 Million SEK | -392.258% |
| Isofol Medical AB (publ) | -138.14 Million SEK | 39.382% |
| I-Tech AB | -83.26 Million SEK | -0.578% |
| Hansa Biopharma AB (publ) | 134.7 Million SEK | 162.166% |
| Cyxone AB (publ) | -16.67 Million SEK | -402.358% |
| ExpreS2ion Biotech Holding AB (publ) | -55.88 Million SEK | -49.846% |
| Biosergen AB | -1.88 Million SEK | -4347.318% |
| Cantargia AB (publ) | -139.74 Million SEK | 40.075% |
| NextCell Pharma AB | -46.79 Million SEK | -78.974% |
| Xspray Pharma AB (publ) | -129.49 Million SEK | 35.331% |
| Elicera Therapeutics AB (publ) | -29.38 Million SEK | -185.005% |
| Nanologica AB (publ) | -9.38 Million SEK | -792.022% |
| SynAct Pharma AB | -61.75 Million SEK | -35.599% |
| Annexin Pharmaceuticals AB (publ) | -21.41 Million SEK | -291.048% |
| Stayble Therapeutics AB (publ) | -13.22 Million SEK | -533.017% |
| LIDDS AB (publ) | -13.51 Million SEK | -519.768% |
| Lipum AB (publ) | -8.46 Million SEK | -889.285% |
| BioInvent International AB (publ) | -236.3 Million SEK | 64.561% |
| Alzinova AB (publ) | -21.22 Million SEK | -294.53% |
| Oncopeptides AB (publ) | -66.92 Million SEK | -25.139% |
| Pila Pharma AB (publ) | -5.18 Million SEK | -1516.373% |
| Guard Therapeutics International AB (publ) | -83.74 Million SEK | -0.002% |
| Scandinavian ChemoTech AB (publ) | -923 Thousand SEK | -8972.914% |
| Simris Alg AB (publ) | 85.07 Million SEK | 198.434% |
| Diamyd Medical AB (publ) | -82.08 Million SEK | -2.019% |
| Xbrane Biopharma AB (publ) | 166.07 Million SEK | 150.424% |
| Ascelia Pharma AB (publ) | -20.79 Million SEK | -302.746% |
| Diagonal Bio AB (publ) | -2.97 Million SEK | -2717.732% |